Adriana Zeevi, PhD, ABHI (D)
Professor of Pathology, Surgery and Immunology

Dr. Zeevi is the Director of the Tissue Typing Laboratory that provides 24hr/ 7 day service to the solid organ and bone marrow transplant program at UPMC, VA and Children's. She provides consultation regarding the sensitization status of potential transplant candidates and their status post-transplant. In addition, Dr. Zeevi engages in teaching activities to graduate students, nursing staff, fellows and clinicians. Dr. Zeevi is also the director of the Pathology Resident rotation and she coordinates other fellow/clinician rotations through the clinical laboratory. Dr. Zeevi has administrative duties in relationship with the clinical tissue typing laboratory and also serves on several Departmental committees. In addition to clinical service, Dr. Zeevi is conducting NIH funded research in collaboration with other investigators in area of her expertise of immune monitoring post transplant.

Office Location:
3477 Euler Way
Room 4033
Pittsburgh, PA 15213

Contact Information:
Office Phone: 412-647-6266
Fax: 412-647-6151


  • BA - 1973, Bar-llan University, Ramat-Gan, Israel
  • MS - 1974, Bar-llan University, Ramat-Gan, Israel
  • PhD - 1979, Bar-llan University, Ramat-Gan, Israel

Clinical Expertise

Dr Zeevi's clinical expertise is in the area of Immunogenetics and Histocompatibility. Shye is the Clinical Director of Tissue Typing Laboratory that serves the transplant program and provides consultation for all solid organ and bone marrow transplantation. An important aspect of her clinical expertise is to characterize the humoral sensitization and rejection in solid organ transplants. IDr. Zeevi has over 30 years of experience with immune monitoring of solid organ transplant recipients and implementation of various assays and novel approaches to evaluate the efficacy of protocols used to desensitize transplant candidates and/or to treat antibody mediated rejection in solid organ transplant recipients.

Research Interests

Despite improved immunosuppression protocols, most transplant recipients face a variety of complications. Early post-transplant is important to discriminate between infection and rejection. Drug toxicity, chronic rejection and malignancies are long-term complications. Dr. Zeevi's research interests are focused in the area of immunologic monitoring of solid organ transplant recipients.

  1. The role of HLA-specific and non-HLA antibodies in solid organ transplantation.
  2. The implementation of novel Luminex platform C1q binding assay to detect complement fixing donor-specific anti HLA antibodies in patient sera and to correlate this functional assay with clinical outcomes including the efficacy of protocols used to desensitize transplant candidates and/or to treat antibody mediated rejection in solid organ transplant recipients.
  3. Cellular assay to determine the host immune competence and responses to recall antigens (CMV, EBV and other)
  4. Evaluation of T helper cell function and cytokine profile upon stimulation with donor-specific alloantigen.
  5. The impact of cytokine gene polymorphism in solid organ transplantation and its predictive value for individualized immunosuppressive protocols


DIPLOMAT, Laboratory Specialty of Histocompatibility Testing

Awards and Honors

  1. 1982-1984 NIH New Investigator Award
  2. 1984-1984 Co-Chairperson, Workshop on T Cell Cloning
  3. 1989 Young Investigator's Award for Research in the Field of Histocompatibility and Immunogenetics
  4. 2002-2003 President ASHI
  5. 2006-2008 Member of NIH TTT Study Section

Selected Publications

View Dr. Zeevi's publications on PubMed

  1. Kobasgigawa, J Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, Burke M, Czer L, Hiemann N, Kfoury AG, Mancini D, Mohacsi P, Patel J, Pereira N, Platt JL, Reed F, Reinsomen N, Rodriguez ER, Rose ML, Russell SD, Suciu-Foca N, Tallaj J, Taylor DO, Van Bakel A, West L , Adriana Zeevi, Zuckermann A; Consensus Conference Participant. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011: 30: 252-69
  2. Mitsani D, Nyguyen MH, Girnita DM, Spichty K, Kwak EJ, Silveria FP, Toyoda Y, Pilewski JM, Crespo M, Bhama JK, Abdel-Massih R, Zaldonis D, Zeevi Adriana, Clancy CJ. A polymorphism linked to elevated levels of interferon-y is associated with increased risk of cytomegalovirus disease among Caucasian lung transplant recipients at a single center. J Heart Lung Transplant 2011: 30: 523-9
  3. Xue J, Gochuico BR, Alawad AS, Feghali-Bostwick CA, Noth I, Nathan SD, Rosen GD, Rosas IO, Dacic S, Ocak I, Fuhrman CR, Cuenco KT, Smith MA, Jacobs SS, Zeevi Adriana, Morel PA, Pilewski JM, Valentine VG, Gibson KF, Kaminski N, Sciurba FC, Zhang Y, Duncan SR. The HLA class II allele DRB1* 1501 is over-represented in patients with idiopathic pulmonary fibrosis. PLoS One 2011 23: 6-e14715
  4. Castellaneta A, Mazariegos GV, Nayyar N, Zeevi Adriana, Thomson AW. HLA-G level on monocytoid dendritic cells correlates with regulatory T-cell Foxp3 expression in liver transplant tolerance. Transplantation 2011: 91: 1132-40
  5. Girnita DM, Ohmann EL, Brooks MM, Webber SA, Burckart GJ, Ferrell RE, Ranganathan S, Chinnock R, Canter C, Addonizio L, Bernstein D, Kirklin JK, Naftel DC, Zeevi Adriana. Gene polymorphisms impact the risk of rejection with hemodynamic compromise: A multicenter study. Transplantation 2011: 91: 1326-1332
  6. Feingold B, Raval JS, Galambos C, Yazer M, Zeevi Adriana Bentlejewski C, Morell VO, Wearden PD, Webber SA. Tolerance to incompatible ABO blood group antigens is not observed following homograft implantation. Hum Immunol. 2011: 72: 835-40
  7. Ashokkumar C,Ningappa M, Ranganathan S, Higgs BW, Sun Q, Schmitt L, Snyder S,Dobberstein J, Bronca M, Jafffe R, Zeevi Adriana, Squires R, Allissa F, Shneider B, Soltys K, Bond G, Abu-Elmagd K, Humar A, Mazariegos G, Hakoarson H, Sindhi R. Increased expression of peripheral blood leukocyte genes implicate CD14 (+) tissue macrophages in cellular intestine allograft rejection. AM J Pathol 2011: 179: 1929- 38
  8. Basu A, Falcone J, Dvorchik I, Tan HP, Schonder K, Marsh JW, Zeevi Adriana, Humar A, Shaprio R. Outcomes of renal transplantation in recipients with peak panel reactive antibody >30% under tacrolimus-based immunosuppression. Ann Transplant. 2011: 16: 5-13
  9. Batal I, Azzi J, El-haddad N, Riella LV, Lunz JG 3RD , Zeevi Adriana, Sasatomi E, Basu A, Tan H, Shapiro R, Randhawa P. Immunohistochemical markers of tissue injury in biopsies with transplant glomerulitis. Hum Pathol 2012: 43: 69-80
  10. Zeevi Adriana, Marrari M, Feingold B, Webber S, Duquesnoy RJ. Human leukocyte antigen epitope analysis complement-and non-complment -binding donor-specific antibody repertoire in a pediatric heart transplant recipient. Hum Immunol. 2012: 73: 48-51
  11. Sindhi R, Ashokkumar C, Higgs BW, Gilbert PB, Sun Q, Ranganathan S, Jaffe R, Synder S, Ningappa M, Soltys KA, Bond GJ, Mazariegos GV, Abu-Elmagd K, Zeevi Adriana. Allospecific CD154 + T-cytotoxic memeory cells as potential surrogate for rejection risk in pediatric intenstine transplantation. Pediatr Transplant 2012 16: 83-91
  12. Macedo C, Walters JT, Orkis EA, Isse K, Elinoff BD, Fedorek SP, McMichael JM, Chalasani G, Randhawa P, Demetris AJ, Zeevi Adriana, Tan H, Shapiro R, Landsittel D, Lakkis FG, Metes D. Long-Term effects of alemtuzumab on regulatory and memory T-Cell subsets in kidney transplantation. Transplantaiton 2012 93: 813-21
  13. Yousem SA, Zeevi Adriana. The histopathology of lung allograft dysfunction associated with development of donor-specifice HLA antibodies. Am J Surg Pathol 2012 36: 987-92
  14. Ranganathatn S, Zeevi Adriana, Ozolek J, Venkat V, Soltys K, Mazariegos G, Sindhi R. Autoimmunity autoimmunity, and chronic liver allograft injury. Pediatr Transplant. 2012 16: 402-403
  15. Feingold B. Brooks MM, Zeevi Adriana, Ohmann EL, Burckart GJ, Ferrell RE, Chinnock R, Canter C, Addonizio L, Bernstein D, Kirklin JK, Naftel DC, Webber SA. Reneal function and gentic polymorphisms in pediatric heart transplant recipients. J Heart Lung Transplant 2012 31: 1003-8
  16. Zeevi Adriana, Lunz J. HLA antibody profiling in thoracic transplantation undergoing desensitization therapy. Curr Opin Organ Transplant. 2012 17: 416-22
  17. KM Abu-Elmagd, G Wu, G. Costa, J Lunz, L Maring, DA Koritsky, N Murase, W Irish and Zeevi Adriana. Preformed and De Novo donor specific antibodies in viscera transplantation: Long-Term outcome with special reference to the liver. Am J Transplant: 2012 12: 3047-3060
  18. Ningappa M, Ashokkumar C, Ranganathan S, Schmitt L, Higgs BW, Sun Q, Branca M, Mazariegos G, Zeevi Adriana, Abu-Elmagd K, Squires R, Rudolph J, Alissa F, Hakonarson H, Sindi R. Mucosal plasma cell barrier disruption intestine transplant rejection. Transplantation 2012 94: 1236-42
  19. Schneeberger S, Gorantla VS, Brandacher G, Zeevi Adriana, Demetris AJ, Lunz JG, Metes DM, Donnenberg AD, Shores JT, Dimartini AF, Kiss JE, Imbriglia JE, Azari K, Goitz RJ, Manders EK, Nguyen VT, Cooney DS, Wachtman GS, Keith JD, Fletcher DR, Macedo C, Planinsic R, Losee JE, Shaprio R, Starzl TE, Lee WP. Upper-extremity transplantation using a cell-based protocol to mininize immunosuppression. AM Surg. 2013 257: 345-351
  20. Xu Y, Galambos C, Reyes-Múgica M, Miller SA, Zeevi Adriana, Webber SA, Feingold B. Utility of routine C4d immunostaining in the first year after pediatric and young adult heart transplantation. J Heart Lung Transplant 2013 32: 92-7
  21. Tait BD, Süsal C, Gebel HM, Nickerson PW, Zachary AA, Class FH, Reed EF, Bray RA, Campbell P, Chapman JR, Coates PT, Colvin RB, Cozzi E, Doxiadis II, Fuggle SV, Gill J, Glotz D, Lachmann N, Mohanakumar T, Suciu-Foca N, Sumitran-Holgersson S, Tanabe K, Taylor CJ,Tyan DB, Webster A, Zeevi Adriana Opelz G. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013 95: 19-47
  22. Zeevi Adriana, Lunz J, Feingold B, Shullo M, Bermudez C, Teuteberg J, Webber S. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant 2013 32: 98-105
  23. Rimmele T, Kaynar AM, McLaughlin JN, Bishop JV, Fedorchak MV, Chuasuwan A, Peng Z, Singbartl K, Frederick DR, Zhu L, Carter M, Federspiel WJ, Zeevi Adriana Kellum JA. Leukocyte capture and modulation of cell mediated immunity during human sepsis: an ex vivo study. Crit Care 2013 17 (2)-R59
  24. Lefaucheur C, Loupy A, Zeevi Adriana Complement-binding anti-HLA antibodies and kidney transplantation. N Engl J Med. 2014 370: 85-6
  25. Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, Castro MC, David DS, David-Neto E, Bagnasco SM, Cendales LC, Cornell LD,Demetris AJ, Drachenberg CB, Farver CF, Farris AB 3rd, Gibson IW, Kraus E, Liapis H, Loupy A, Nickeleit V, Randhawa P, Rodriguez ER, Rush D, Smith RN, Tan CD, Wallace WD, Mengel M :Banff meeting report writing committee. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arteral lesions. AM J Transplant. 2014 14: 272-83
  26. Burckart GJ, Figg WD 2nd, Brooks MM, Green DJ, Troutman SM, Ferrell R, Chinnock R, Canter C, Addonizio L, Bernstein D, Kirklin JK, Naftel D, Price DK, Sissung TM, Girnita DM, Zeevi Adriana, Webber SA. Multi-institutional study of outcomes after pediatric heart transplantation: Candidate gene polymorphism analysis of ABCC2. J Pediatr Pharmacaol Ther. 2014 19: 16-24